DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia ...

NMDA receptors are present throughout the brain and are essential for maintaining consciousness. For this reason, she ...

Drug Discov. 7 426–437; 2008). Increased levels of glutamate have been found in the frontal cortex of patients with MDD, and the non-selective NMDA receptor antagonist ketamine has shown ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Now ketamine, a glutamatergic NMDA receptor antagonist, may provide a mechanism that could link these pathways. Figure 1: A schematic of how ketamine may lead to an overall excitation in the cortex.

There are now ketamine clinics nationwide where the drug is given intravenously to treat depression. Like a lock and key, ketamine binds to the brain via N-methyl-D-aspartate (NMDA) receptors.

The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

NMDA receptors, members of the excitatory ionotropic glutamate receptor family, are essential to these processes. They regulate the strength of synaptic connections, playing a critical role in ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray Spravato (esketamine) as a standalone treatment ...

Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.